[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kudo Y, Terao H, Arita T, Kawasaki H, Sato S, Abe H, Kodama M, Fujioka T, Murakami K, Nasu M: Interferon therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after treatment of recurrent hepatocellular carcinoma: a successful case. Intern Med; 2002 Mar;41(3):202-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after treatment of recurrent hepatocellular carcinoma: a successful case.
  • A complete response was obtained by interferon (IFN) therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after curative treatment of initial and recurrent hepatocellular carcinoma (HCC).
  • This case suggest that it is possible to suppress recurrence and to prolong the life of patients with HCV-related advanced chronic hepatitis, if a complete response is obtained by means of IFN therapy after the curative treatment of the recurrent HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Hepatitis C, Chronic / drug therapy. Interferons / therapeutic use. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11929181.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


2. Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh C, Schaffer RL: Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol; 2006 Sep 21;12(35):5729-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.
  • Hepatocellular carcinoma (HCC) recurs with a reported frequency of 12%-18% after liver transplantation.
  • Approximately one-third of recurrences develop in the transplanted liver and are therefore amenable to local therapy.
  • A variety of treatment modalities have been reported including resection, transarterial chemo-embolization (TACE), radiofrequency ablation (RFA), ethanol ablation, cryoablation, and external beam irradiation.
  • Goals of treatment are tumor control and the minimization of toxic effect to functional parenchyma.
  • Efficacy of treatment is mitigated by the need for ongoing immunosuppression.
  • Yttrium-90 microspheres have been used as a treatment modality both for primary HCC and for pre-transplant management of HCC with promising results.
  • Twenty-two months after liver transplantation for hepatitis C cirrhosis complicated by HCC, a 42-year old man developed recurrence of HCC in his transplant allograft.
  • Treatment of multiple right lobe lesions with anatomic resection and adjuvant chemotherapy was unsuccessful.
  • Multifocal recurrence in the remaining liver allograft was treated with hepatic intra-arterial infusion of yttrium-90 microspheres (SIR-Spheres, Sirtex Medical Inc., Lake Forest, IL, USA).
  • There were no adverse consequences of initial treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Hepatitis C. Humans. Infusions, Intra-Arterial. Liver Transplantation. Male. Microspheres. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] Transplantation. 2002 Dec 27;74(12):1746-51 [12499891.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10 [14762849.001]
  • [Cites] Psychooncology. 2004 Feb;13(2):73-9 [14872525.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1127-31 [16123954.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203 [15713920.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] Arch Surg. 2005 Apr;140(4):353-8 [15837885.001]
  • [Cites] Liver Transpl. 2004 Apr;10(4):534-40 [15048797.001]
  • (PMID = 17007031.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ PMC4088179
  •  go-up   go-down


3. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG, Lau WY, Li AK: Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol; 2003 Jun;162(6):1823-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.
  • The aim of this study is to determine the status of the p53 gene in recurrent human hepatocellular carcinoma (HCC) and test the link between the expression of ZBP-89 and the p53 gene.
  • The results showed that mutations in the p53 gene were frequently detected in recurrent HCC.
  • The interval between surgical resection and the recurrence of HCC was significantly longer in patients with the wild-type p53 gene than those with mutations, strongly suggesting a pathological role for the mutant p53 gene in HCC recurrence.
  • ZBP-89 co-localized with p53 in the nucleus in about 67% (12 of 18) of all cases positive for the nuclear p53 protein, suggesting that ZBP-89 may play a role in the nuclear accumulation of the p53 protein in a subset of recurrent HCC.
  • With accumulation of p53 protein in the nucleus, tumor cells undergo apoptosis and thus are more susceptible to radiotherapy and chemotherapy.
  • Therefore, co-localization of p53 protein with ZBP-89 may define a subgroup of recurrent HCC that is more sensitive to treatment.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 1;88(7):1565-73 [10738214.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4670-83 [11416144.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3717-26 [10949925.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30725-33 [10899165.001]
  • [Cites] Arch Surg. 2000 Nov;135(11):1329-33 [11074891.001]
  • [Cites] Cell. 2000 Nov 22;103(5):691-4 [11114324.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):145-59 [11218912.001]
  • [Cites] Chem Res Toxicol. 2001 Mar;14(3):243-63 [11258974.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):332-7 [11343904.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):231-43 [11407595.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1695-702 [11527698.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2449-56 [8361758.001]
  • [Cites] Nat Genet. 1993 Nov;5(3):225-9 [8275085.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):30-7 [8004579.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3718-22 [8033090.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):137-9 [7520014.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1235-46 [7926727.001]
  • [Cites] Science. 1994 Nov 4;266(5186):807-10 [7973635.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):790-8 [7677190.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1387-93 [8875976.001]
  • [Cites] DNA Cell Biol. 1996 Oct;15(10):793-803 [8892752.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Apr 7;233(1):154-60 [9144414.001]
  • [Cites] Oncogene. 1997 Jul 3;15(1):63-70 [9233778.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):776-82 [9514057.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):19955-64 [9685330.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1279-88 [9891062.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):477-85 [9927204.001]
  • [Cites] Hepatology. 1999 Mar;29(3):697-702 [10051470.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):189-94 [10096428.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2501-3 [10470182.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):353-6 [10888421.001]
  • (PMID = 12759240.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK055732; United States / NIDDK NIH HHS / DK / R56 DK055732; United States / NIDDK NIH HHS / DK / DK 55732
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / ZNF148 protein, human
  • [Other-IDs] NLM/ PMC1868140
  •  go-up   go-down


Advertisement
4. Ikushima I, Higashi S, Seguchi K, Ishii A, Ota Y, Shima M, Kanemaru M, Hidaka Y: Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Eur J Radiol; 2009 Jan;69(1):114-9
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy.
  • PURPOSE: To evaluate the midterm results of transarterial infusion (TAI) with water-in-oil-in-water (W/O/W) emulsion containing an anticancer agent for patients with recurrent hepatocellular carcinoma (HCC) after surgical resection.
  • MATERIALS AND METHODS: We retrospectively analyzed the results of TAI of W/O/W emulsion containing epirubicin for 18 consecutive patients with recurrent HCC after surgical resection.
  • Angiographically, recurrent HCC appeared a single nodule in nine patients and was multinodular in other nine patients.
  • Survival time was defined as the time from the date of first TAI to the date of death or last follow-up (median follow-up time: 17 months) and the survival curve was estimated using the Kaplan-Meier method.
  • Survival from the time of initial TAI was 94% at 1 year, 76% at 2 years, and 76% at 3 years.
  • CONCLUSIONS: TAI of W/O/W emulsion may be an effective treatment for patients with recurrent HCC after surgical resection.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Epirubicin / administration & dosage. Hepatectomy. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Drug Carriers / chemistry. Emulsions / chemistry. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Oils / chemistry. Treatment Outcome. Water / chemistry

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17935921.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Emulsions; 0 / Oils; 059QF0KO0R / Water; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


5. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol; 2002 Jul;80(3):143-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein.
  • BACKGROUND AND OBJECTIVES: This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT).
  • METHODS: Seven unresectable or recurrent HCC patients with PVTT were enrolled in this study.
  • A one-week course of chemotherapy consisted of intraarterial administration of CDDP (10 mg on days 1-5) for 1 h and 5-FU (250 mg on days 1-5) for 24 h, followed by cessation of administration for the subsequent 2 days (days 6 and 7).
  • Three or more sequential courses of chemotherapy were given through an implanted reservoir.
  • RESULTS: Serum alpha-fetoprotein (AFP) levels before the chemotherapy were >20 ng/ml in six of the seven patients.
  • Serum AFP levels were decreased in four of the six patients after chemotherapy, including two patients (cases 1 and 7) whose AFP levels later returned to normal.
  • Six of the seven patients had measurable lesions in the liver, with a response rate of 33%.
  • In three of the seven patients (43%), PVTTs decreased in size or disappeared after chemotherapy.
  • CONCLUSIONS: The chemotherapy described in this report is beneficial in terms of survival for HCC patients with PVTT for whom transcatheter arterial embolization or surgical treatment is contraindicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Infusion Pumps, Implantable. Liver Neoplasms / drug therapy. Neoplastic Cells, Circulating / pathology. Portal Vein / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12115797.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


6. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ: Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol; 2009 May;24(5):800-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.
  • BACKGROUND AND AIM: The majority of patients with post-transplantation recurrence of hepatocellular carcinoma (HCC) have extrahepatic metastases and multifocal lesions.
  • Therefore, they have few treatment options and may not be amenable for local therapy.
  • The safety and efficacy of palliative chemotherapy in this population has not been reported.
  • METHODS: We retrospectively analyzed 24 patients who received palliative chemotherapy for recurrent HCC after liver transplantation between January 2000 and December 2006 at the Seoul National University Hospital.
  • The Grade 3/4 non-hematological toxicity included elevation of liver transaminase (8.4%) and jaundice (16.7%).
  • The median time to progression was 7.0 weeks (95% CI 5.8-8.2) and the median overall survival was 16.6 weeks (95% CI 10.1-23.1).
  • CONCLUSION: Palliative chemotherapy can be delivered to patients with recurrent HCC after liver transplantation with tolerable toxicity.
  • Therefore, more effective systemic chemotherapy is needed for this group of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Liver Transplantation. Neoplasm Recurrence, Local. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Failure. Treatment Outcome


7. Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, Park KU, Kim YJ, Yoon JH, Lee HS: High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant; 2010 Jul;10(7):1649-59
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence.
  • Hepatitis B virus (HBV) recurrence following orthotopic liver transplantation (OLT) is generally preventable by prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine (LAM).
  • Posttransplant HBV recurrence occurred in 22 patients (10.5%), including 13 patients with drug-resistant mutations.
  • HBV recurrence was observed in six patients after hepatocellular carcinoma (HCC) recurrence.
  • Independent predictors of HBV recurrence were recurrent HCC (p < 0.001), LAM therapy >1.5 years (p = 0.001) and high HBV DNA titers (> or =10(5) copies/mL) at OLT (p = 0.036).
  • [MeSH-major] Hepatitis B / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adult. DNA, Viral / analysis. DNA, Viral / genetics. Drug Therapy, Combination. Female. Hepatitis B virus / genetics. Humans. Immunization, Passive. Immunoglobulins / therapeutic use. Lamivudine / adverse effects. Lamivudine / therapeutic use. Male. Middle Aged. Mutation. Predictive Value of Tests. Recurrence. Retrospective Studies. Reverse Transcriptase Inhibitors / adverse effects. Reverse Transcriptase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20642687.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunoglobulins; 0 / Reverse Transcriptase Inhibitors; 0 / hepatitis B hyperimmune globulin; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


8. Kornberg A, Küpper B, Tannapfel A, Thrum K, Wilberg J, Bärthel E, Settmacher U: Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - preliminary results. Transpl Int; 2008 Jan;21(1):96-9
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - preliminary results.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Liver Transplantation. Neoplasm Recurrence, Local / drug therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Follow-Up Studies. Humans. Immunosuppressive Agents. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903182.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


9. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK: Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol; 2010 Aug;40(8):768-73
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
  • OBJECTIVE: Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials.
  • The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined.
  • METHODS: We retrospectively analyzed 13 patients who were treated with sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
  • RESULTS: The median time to recurrence from liver transplantation was 12.3 months (95% confidence interval: 8.5-16.1 months).
  • At a median follow-up duration of 3.7 months (range: 0.3-10.9 months) in surviving patients, the median time to progression and the median overall survival from commencement of sorafenib were 2.9 months (95% confidence interval: 0.0-6.8 months) and 5.4 months (95% confidence interval: 3.7-7.0 months), respectively.
  • CONCLUSIONS: These findings suggest that sorafenib may be a feasible treatment option regarding its efficacy and safety for recurrent hepatocellular carcinoma after liver transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Disease Progression. Drug Eruptions / etiology. Female. Hematologic Diseases / chemically induced. Humans. Liver Transplantation. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494947.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


10. Tanabe G, Ueno S, Maemura M, Kihara K, Aoki D, Yoshidome S, Ogura Y, Hamanoue M, Aikou T: Favorable quality of life after repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology; 2001 Mar-Apr;48(38):506-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable quality of life after repeat hepatic resection for recurrent hepatocellular carcinoma.
  • BACKGROUND/AIMS: The appropriate choice of treatment for recurrent hepatocellular carcinoma after hepatic resection remains controversial.
  • The aim of this study is to clarify prognostic factors and quality of life in patients with tumor recurrence after hepatic resection for hepatocellular carcinoma.
  • METHODOLOGY: We retrospectively analyzed 188 patients with hepatocellular carcinoma who underwent curative hepatic resection between 1988 and 1997.
  • Furthermore, quality of life after treatment for recurrence was compared between patients with repeat hepatic resection or hepatic arterial infusion chemotherapy.
  • RESULTS: In 123 patients with recurrence, unfavorable predictors after recurrence are pTNM Stage III/IV at initial surgery, receiving chemotherapy before initial surgery and presence of extrahepatic recurrence.
  • The incidence of deteriorated performance status in the repeat hepatic resection group was lower than in the hepatic arterial infusion chemotherapy group because of better psychological function in patients undergoing repeat hepatic resection.
  • CONCLUSIONS: Repeat hepatic resection provides a good prognosis and a favorable quality of life in patients with recurrence after hepatic resection for hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379343.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Katsuramaki T, Furuhata T, Kimura Y, Yamaguchi K, Ohmura T, Hata F, Mukaiya M, Hirata K: [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. Gan To Kagaku Ryoho; 2002 Oct;29(10):1801-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
  • We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously.
  • A 49-year-old Japanese man who underwent a right hepatectomy for HCC developed tumor recurrence in the liver 19 months after surgery.
  • Abdominal CT revealed multiple metastatic lesions in the liver.
  • He received a combination therapy of 500 mg/day of 5-FU that was given intravenously by continuous infusion and 5 x 10(6) units of IFN-alpha, given three times weekly.
  • The treatment resulted in a fall in serum PIVKA-II (protein induced by vitamin K antagonism) levels from 337 mAU/ml to 65 mAU/ml and disappearance of tumor stain in enhanced CT.
  • 5-FU is usually administered by arterial infusion in a combination therapy of IFN-alpha and 5-FU.
  • However, 5-FU infusion may be possible intravenously in the combination therapy of IFN-alpha and 5-FU for the treatment of advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Interferon-alpha / administration & dosage. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402433.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Liu Y, Wu M, Qian G, Zhang B, Chen H, Fu J, Huang C: Changes and significance of circulating hepatocellular carcinoma cells in recurrent hepatocellular carcinoma patients after combined treatment. Zhonghua Gan Zang Bing Za Zhi; 2001 Feb;9(1):40-1
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes and significance of circulating hepatocellular carcinoma cells in recurrent hepatocellular carcinoma patients after combined treatment.
  • OBJECTIVE: To study the changes and significance of circulating hepatocellular carcinoma cells in recurrent hepatocellular carcinoma (HCC) patients after combined treatment of transarterial chemo-embolization(TACE) and percutaneous ethanol injection(PEI).
  • METHODS: We detected 19 blood samples from the recurrent HCC patients by nested RT-PCR to find out AFP mRNA before and after the treatment.
  • RESULTS: There were 7 patients with AFP mRNA positive before treatment (36.8%), and none of patients with AFP mRNA positive after treatment.
  • CONCLUSIONS: Combined treatment of TACE and PEI can effectively eliminate circulating hepatocellular carcinoma cells and thereby prevent metastasis and recurrence of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Neoplastic Cells, Circulating / drug effects
  • [MeSH-minor] Adult. Chemoembolization, Therapeutic. Ethanol / administration & dosage. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. alpha-Fetoproteins / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242135.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / alpha-Fetoproteins; 3K9958V90M / Ethanol
  •  go-up   go-down


13. Matsushita A, Hanazaki K, Noike T, Nakagawa K, Misawa R, Nakata T, Nomura K, Kobayashi A, Miwa S, Miyagawa S, Kawasaki S: [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1327-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection].
  • UFT is an anti-cancer drug which combines uracil with tegafur at a mole rate of 1:4, and shows a high anti-tumor effect by raising the 5-FU level in a tumor.
  • The preoperative diagnosis was giant hepatocellular carcinoma (HCC) of the right hepatic anterior region, and extended anterior segmentectomy of the liver was performed.
  • Three months later, serum alpha-fetoprotein (AFP) and PIVKA-II were elevated markedly, and computed tomography (CT) and magnetic resonance imaging (MRI) revealed a recurrence in the remnant liver and multiple lung metastasis.
  • Chemotherapy with oral UFT (300 mg/day) administration alone was started for the unresectable HCC.
  • Three months later, CT and MRI showed complete disappearance of the recurrent HCC and multiple lung metastasis.
  • This case suggests that oral UFT administration is a safe and effective therapy for postoperative HCC, even with lung metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Biomarkers, Tumor / blood. Drug Administration Schedule. Humans. Male. Middle Aged. Protein Precursors / blood. Prothrombin. Tegafur / administration & dosage. Uracil / administration & dosage. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518415.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 1548R74NSZ / Tegafur; 53230-14-1 / acarboxyprothrombin; 56HH86ZVCT / Uracil; 9001-26-7 / Prothrombin; 1-UFT protocol
  • [Number-of-references] 16
  •  go-up   go-down


14. Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F: Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology; 2010;79(1-2):62-6
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
  • BACKGROUND AND AIM: The majority of patients who undergo orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) have a very good prognosis if the tumor is within the Milan criteria.
  • RESULT: The median age at the time treatment with sorafenib was initiated was 59 years (range 46-77).
  • Two patients received prior local therapy.
  • Most of the toxicity was expected side effects from sorafenib except in 1 patient who developed hematological toxicity.
  • There were no unexpected complications from interaction with immunosuppressive medication.
  • Median survival from the start of sorafenib had not been reached at the time of writing; however, the 4-month survival rate is currently estimated to be 84 ± 15%, and 1 patient with lung reoccurrence has been treated for almost 18 months thus far.
  • CONCLUSION: Sorafenib can be used in patients with recurrent HCC after liver transplantation with tolerable toxicity; however, dose adjustment may be required.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Benzenesulfonates / administration & dosage. Benzenesulfonates / adverse effects. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation. Neoplasm Recurrence, Local / drug therapy. Pyridines / administration & dosage. Pyridines / adverse effects
  • [MeSH-minor] Aged. Drug Administration Schedule. Feasibility Studies. Humans. Immunosuppressive Agents / administration & dosage. Male. Medical Records. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21071991.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Immunosuppressive Agents; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


15. Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH: A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract. Integr Cancer Ther; 2010 Mar;9(1):100-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract.
  • There is no established protocol proven to be beneficial for treatment of hepatocellular carcinoma recurrence after liver transplantation.
  • Only a few reports have shown direct treatment by surgery or ablation to be independent predictors of survival for localized recurrence.
  • Moreover, the necessity of immunosuppression to prevent allograft rejection makes many physicians hesitate to administer systemic chemotherapy.
  • This case report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, was associated with a decrease in the size of lung metastases in a patient with recurrent hepatocellular carcinoma after liver transplantation refractory to doxorubicin.
  • This patient experienced prolonged survival compared with average survival times and little toxicity.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Doxorubicin / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / drug therapy. Liver Transplantation. Rhus
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Resistance, Neoplasm / drug effects. Herbal Medicine. Humans. Male. Middle Aged. Recurrence. Remission Induction / methods. Treatment Failure

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Integr Cancer Ther. 2010 Mar;9(1). doi: 10.1177/1534735411416420. Kim, Hye Ryun [removed]
  • [ErratumIn] Integr Cancer Ther. 2011 Sep;10(3):299
  • (PMID = 20308087.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Baba H, Matsumoto G, Tsuruta K, Okamoto A, Hara Y, Endo M, Irie T, Arii S: [Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1705-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma].
  • A 52-year-old male patient was admitted to our hospital for a further examination of liver tumor.
  • CT scanning revealed two hyper vascular tumors at the lateral segment of the liver and another one located at segment 8, an indication of hepatocellular carcinoma (HCC).
  • Lateral segmentectomy and a partial resection of the segment 8 were performed at the same time.
  • Arterial infusion chemotherapy using CDDP (10 mg), 5-FU (1,000 mg) and IFN-beta 3MU (continuous infusion for 5 days) was started two months later, and a complete response was achieved.
  • The chemotherapy continued as long as severe adverse effects were not observed.
  • However, two months after the tumor disappearance, the treatment discontinued due to occlusion of the infusion system.
  • In conclusion, these results suggest that arterial chemotherapy using CDDP/5-FU/IFN-beta against HCC may be beneficial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Interferon-beta / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553689.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Terasaki T, Hanazaki K, Shiohara E, Matsunaga Y, Koide N, Amano J: Complete disappearance of recurrent hepatocellular carcinoma with peritoneal dissemination and splenic metastasis: a unique clinical course after surgery. J Gastroenterol Hepatol; 2000 Mar;15(3):327-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete disappearance of recurrent hepatocellular carcinoma with peritoneal dissemination and splenic metastasis: a unique clinical course after surgery.
  • Spontaneous regression of hepatocellular carcinoma (HCC) is a rare phenomenon.
  • We report a case of complete disappearance of intrahepatic, peritoneal and splenic metastases in HCC after hepatectomy using treatment with tegafur and uracil (UFT).
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Peritoneal Neoplasms / physiopathology. Splenic Neoplasms / physiopathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Drug Therapy, Combination. Female. Humans. Magnetic Resonance Imaging. Remission Induction. Tegafur / therapeutic use. Tomography, X-Ray Computed. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764038.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


18. Hoshida Y, Shiratori Y, Omata M: Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. Liver; 2002 Dec;22(6):479-85
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.
  • BACKGROUND: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma.
  • DESIGN: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence.
  • RESULTS: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of dollars 77000, and an incremental cost-effectiveness ratios of dollars 15700/life year compared with no interferon therapy.
  • The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6% to 62.9% using adjuvant interferon therapy.
  • The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy.
  • A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = dollars 27000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16% (baseline 8.9%).
  • The proportions of patients with recurrent hepatocellular carcinoma were 74.4% and 86.9% at the annual recurrence rates after interferon of 16% and 35%, respectively.
  • CONCLUSIONS: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.
  • [MeSH-major] Antiviral Agents / economics. Carcinoma, Hepatocellular / economics. Hepatitis C / economics. Interferons / economics. Liver Neoplasms / economics
  • [MeSH-minor] Chemotherapy, Adjuvant. Cost-Benefit Analysis. Humans. Life Expectancy. Liver Cirrhosis / drug therapy. Liver Cirrhosis / economics. Liver Cirrhosis / etiology. Male. Markov Chains. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445173.001).
  • [ISSN] 0106-9543
  • [Journal-full-title] Liver
  • [ISO-abbreviation] Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  •  go-up   go-down


19. Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T: Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci; 2007 Mar;52(3):783-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma.
  • We compared the growth rate of locally recurrent hepatocellular carcinoma (HCC) with that of primary HCC.
  • After the first treatment by transcatheter arterial chemoembolization (TACE), 60 locally recurrent HCC nodules were reviewed.
  • The tumor volume doubling time (DT) of locally recurrent HCC was significantly shorter than that of primary HCC.
  • Locally recurrent HCCs cannot double in diameter in less than 53 days.
  • In the case that an equivocal lesion smaller than the section collimation depicted during a contrast-enhanced computed tomography (CECT) screening cannot be ruled out as local recurrence, the next CECT screening should be performed 2 months later.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bromhexine. Chemoembolization, Therapeutic. Female. Humans. Male. Middle Aged. Radiographic Image Enhancement

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Feb;226(2):550-5 [12563153.001]
  • [Cites] Abdom Imaging. 2002 Mar-Apr;27(2):147-56 [11847574.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Jan;17(1):52-8 [11895553.001]
  • [Cites] Radiology. 2001 Mar;218(3):763-7 [11230652.001]
  • [Cites] Hepatology. 1992 Jul;16(1):132-7 [1352268.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):893-901 [8813771.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):259-66 [2408960.001]
  • [Cites] Hepatology. 1995 Jul;22(1):101-5 [7601399.001]
  • [Cites] Dig Dis Sci. 2003 Mar;48(3):587-93 [12757174.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):92-9 [11823978.001]
  • [Cites] Radiology. 1993 Dec;189(3):851-5 [8234715.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jun;164(6):1407-12 [7754883.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Hepatogastroenterology. 1998 Aug;45 Suppl 3:1214-20 [9730377.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):580-7 [10801025.001]
  • [Cites] Dig Dis Sci. 2003 Mar;48(3):581-6 [12757173.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1530-4 [7768496.001]
  • [Cites] Cancer. 1961 Nov-Dec;14:1272-94 [13909709.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):289-98 [2416627.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2207-10 [2541886.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):798-9 [10072416.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2095-100 [1655200.001]
  • [Cites] J Hepatol. 1996 Mar;24(3):293-300 [8778195.001]
  • [Cites] J Hepatol. 2005 Aug;43(2):310-6 [15970351.001]
  • [Cites] Radiology. 1996 May;199(2):505-11 [8668803.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Ann Intern Med. 1978 Jul;89(1):107-21 [666155.001]
  • [Cites] Surgery. 1994 Apr;115(4):452-7 [7513088.001]
  • (PMID = 17268830.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


20. Uchida S, Kawashima Y, Horiuchi H, Hayashi K, Okuda K, Kinoshita H, Aoyagi S, Shirouzu K, Yanase A: [A case of radiofrequency ablation therapy for recurrent hepatomas with tumor fever--efficacy of hepatic arterial infusion therapy with antibiotics and anticancer drugs]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1819-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of radiofrequency ablation therapy for recurrent hepatomas with tumor fever--efficacy of hepatic arterial infusion therapy with antibiotics and anticancer drugs].
  • Efficacy of hepatic arterial infusion therapy (HAI) using antibiotics for hepatic abscess has been reported.
  • However, we effectively performed RFA therapy after HAI with antibiotics and anticancer drugs for recurrent hepatomas with tumor fever.
  • A 67-year-old female of recurrent hepatomas with fever is presented here.
  • She was diagnosed with a 6 cm recurrent hepatoma, both in the right and IM lobes.
  • Her liver function was child A with hepatitis C.
  • Initially, we gave systemic medication of antibiotics, but could not decrease the fever.
  • Therefore, we performed HAI with antibiotics and anticancer drugs.
  • After HAI, we were able to completely perform RFA for recurrent hepatomas.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Liver Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Cefmetazole / administration & dosage. Cilastatin / administration & dosage. Cisplatin / administration & dosage. Female. Fever / drug therapy. Hepatic Artery. Humans. Imipenem / administration & dosage. Infusions, Intra-Arterial. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553726.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 141A6AMN38 / Cilastatin; 3J962UJT8H / Cefmetazole; 71OTZ9ZE0A / Imipenem; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Ohmoto K, Mimura N, Iguchi Y, Mitsui Y, Shimabara M, Kuboki M, Yamamoto S: CT-guided percutaneous ethanol injection therapy for ultrasonically invisible hepatocellular carcinoma. Hepatogastroenterology; 2002 Mar-Apr;49(44):297-9
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided percutaneous ethanol injection therapy for ultrasonically invisible hepatocellular carcinoma.
  • We report the case of a 75-year-old woman with hepatitis C virus-related cirrhosis and recurrent hepatocellular carcinoma located just beneath the diaphragm.
  • Computed tomography-guided percutaneous ethanol injection therapy was performed, because images of the tumor were hard to obtain on ultrasonography.
  • The angle and depth of needle insertion were determined by using the geometric relationship between the target lesion and the skin insertion site on computed tomography scans.
  • Computed tomography scanning was repeated to verify the needle position.
  • This procedure caused transient mild pain, but there were no serious adverse effects such as pneumothorax or hemothorax.
  • Three months after treatment, the lesion was not enhanced on dynamic computed tomography scanning, suggesting complete tumor ablation.
  • In conclusion, computed tomography-guided percutaneous ethanol injection therapy was safe and accurately achieved the desired tumoricidal effect in a patient with ultrasonically invisible hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Ethanol / administration & dosage. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Female. Hepatitis C / complications. Humans. Injections, Intralesional / methods. Liver Cirrhosis / complications. Liver Cirrhosis / virology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11995437.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


22. Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, Nakazawa S, Sugano K: Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma. Hepatogastroenterology; 2009 Mar-Apr;56(90):437-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
  • BACKGROUND/AIMS: Recently, complementary alternative medicine is actively performed for cancer therapy.
  • We investigated the effectiveness of supplementary food containing superfine dispersed lentinan (beta-1,3-glucan) in patients with unresectable or recurrent hepatocellular carcinoma in a multi-center study.
  • Patient survival times were followed up for 3 years.
  • Median survival time of eligible patients was 13.6 months (95% confidence interval, 8.7-18.9 months).
  • Survival times of patients who ingested test food for a mean period of 47 weeks (range, 26 to 145 weeks) were significantly longer than that of patients who ingested for 7 to 12 weeks (p < 0.05).
  • Survival times (median survival time, 16.3 months) of lentinan-high-binding group were significantly longer than those (median survival time, 12.5 months) of lentinan-low-binding group (p < 0.05).
  • CONCLUSIONS: A superfine dispersed lentinan-containing supplementary food is effective for hepatocellular carcinoma patients' survival.
  • Long-time ingestion is preferable.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Lentinan / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Dietary Supplements. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579616.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 37339-90-5 / Lentinan
  •  go-up   go-down






Advertisement